The poly (ADP-ribose) polymerase inhibitor olaparib, currently approved for ovarian, fallopian tube, peritoneal and breast BRCA1 and 2-related malignancies and checkpoint kinase inhibitors in tumours with somatic or germline TP53 mutations, are also in clinical trials in children, so we will soon gain further understanding of whether these drugs have true tumour-agnostic potential. Here, TP53 is linked to neoplasm.